Skip to main content
TELCON RF PHARMACEUTICAL. Inc. logo

TELCON RF PHARMACEUTICAL. Inc. — Investor Relations & Filings

Ticker · 200230 ISIN · KR7200230001 KO Manufacturing
Open in API
Filings indexed 351 across all filing types
Latest filing 2026-03-19 Annual Report
Country KR South Korea
Listing KO 200230

About TELCON RF PHARMACEUTICAL. Inc.

http://www.telcon-rf.com

TELCON RF PHARMACEUTICAL. Inc. operates across two primary business segments: radio frequency (RF) components and pharmaceuticals. The RF division specializes in the development, manufacturing, and global sale of components for wireless communication equipment. Its main products include RF coaxial connectors, cable assemblies, coaxial couplers, and distributors. The pharmaceutical and biotechnology division is engaged in the development and sale of medicinal products.

Recent filings

Filing Released Lang Actions
사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is a comprehensive 'Business Report' (사업보고서) for the 27th fiscal year (2025), covering company overview, business details, financial statements, management analysis, and governance. It is a formal, long-form annual filing submitted to the Financial Supervisory Service (FSS) and the Korea Exchange (KRX). In the context of Korean corporate filings, this corresponds to the 10-K equivalent. FY 2025
2026-03-19 Korean
감사보고서제출
Audit Report / Information Classification · 97% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by 텔콘RF제약. It contains key financial data, audit opinions (적정), and financial statements for the fiscal year ending 2025-12-31. While it provides financial summaries, it is a regulatory filing announcing the completion and submission of the audit report to the exchange, rather than the full annual report (10-K) itself. In the context of Korean regulatory filings (DART/KIND), this is classified as an Audit Report/Information filing. FY 2025
2026-03-19 Korean
주주총회소집공고
AGM Information Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Telcon RF Pharmaceutical. It contains the agenda for the upcoming Annual General Meeting (AGM), including items such as the approval of financial statements, election of directors, and auditor appointments. It also includes detailed management information, business overviews, and proxy voting instructions. This document is the official material provided to shareholders to prepare for the AGM, which fits the definition of AGM-R.
2026-03-04 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (Proxy Solicitation Statement) used to request shareholder votes for an upcoming Annual General Meeting (AGM). It includes details on the meeting date, agenda items, and proxy voting procedures. While it contains financial statements, these are provided as supporting information for the meeting agenda rather than as a standalone annual report. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2026-03-04 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 95% confidence The document is a regulatory filing from a Korean company (Telcon RF Pharmaceutical) announcing a significant change in financial results (revenue or profit/loss structure exceeding 30%). This type of disclosure is a standard regulatory requirement in the Korean market (DART system) to inform investors of preliminary financial performance before the final audit is completed. Since it provides key financial highlights and performance metrics rather than a full annual report or a simple announcement of a report's availability, it is classified as an Earnings Release (ER). FY 2025
2026-03-04 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Telcon RF Pharmaceutical. It outlines the date, location, and specific agenda items for the upcoming Annual General Meeting, including the approval of financial statements, election of directors and auditors, and remuneration limits. This type of document is a standard proxy solicitation and information statement provided to shareholders to inform them of meeting details and agenda items.
2026-03-04 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.